Carl Zeiss Meditec AGXSWX:AFX 79 EBITDA Margin % is 0.43% as of Dec. 2025, which is 98% below its 10-year median of 19.57. GuruFocus rates XSWX:AFX with a GF Score™ of 79/100 and a GF Value™ of CHF67.74 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 52.94% on this metric.
Carl Zeiss Meditec AG (XSWX:AFX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Carl Zeiss Meditec AG EBITDA Margin % Related Terms
Carl Zeiss Meditec AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:AFX vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (XSWX:AFX) has a EBITDA Margin % of 0.43% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carl Zeiss Meditec AG and its competitors. This is 98% below median its historical median of 19.57. Over the past decade, Carl Zeiss Meditec AG's EBITDA Margin % has ranged from 8.87 to 25.38. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #384 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 47.1%.
Is Carl Zeiss Meditec AG's EBITDA Margin % too high?
Carl Zeiss Meditec AG's current EBITDA Margin % of 0.43% is 98% below median its 10-year median of 19.57. Over the past 10 years, this metric has ranged from a low of 8.87 to a high of 25.38. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Carl Zeiss Meditec AG's value of 0.43% is 94.2% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #384 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #384 out of 816 companies for EBITDA Margin %. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Carl Zeiss Meditec AG's value of 0.43% is 94.2% below this benchmark. Historically, Carl Zeiss Meditec AG's own EBITDA Margin % has ranged from 8.87 to 25.38 over the past decade. While the company's 10-year median is 19.57 vs. the industry median of 7.48, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current EBITDA Margin % of 0.43% is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current EBITDA Margin % is 0.43%, which is 98% below median its own 10-year median of 19.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF67.74, compared to a current price of CHF24.80 — trading 63.4% below its estimated fair value. The current EBITDA Margin % is 0.43%, which is 98% below median its 10-year median of 19.57 and 94.2% below the Medical Devices & Instruments industry median of 7.48. Carl Zeiss Meditec AG's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current EBITDA Margin % is 0.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF24.80 is trading 63.4% below its estimated GF Value™ of CHF67.74.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
EBITDA Margin %: 0.43% (98% below median its 10-year median of 19.57)
GF Value™: CHF67.74 vs. price of CHF24.80 (63.4% below fair value)
Industry Position: 94.2% below the Medical Devices & Instruments median (#384 of 816)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
79GF Score
Get the complete analysis for XSWX:AFX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
